Trivarx

Non-Executive Chairman David Trimboli commented on TrivarX securing firm commitments to raise $2.25M to fund a clinical trial with the U.S. Department of Veterans Affairs and ongoing R&D initiatives: #TRI #mentalhealth #ASX #ASXnews https://lnkd.in/g7N6cq_V

TrivarX (ASX: TRI) secures $2.25M via a strongly supported Placement at $0.015/share. Funds will advance its clinical trial with GLAVREF & US VA, using its ECG-based mental health screening algorithm. Additional capital supports R&D, regulatory, & commercial efforts. https://lnkd.in/g7N6cq_V #TRI #ASX #investing #news #health #ASXnews

TrivarX (ASX: TRI) is set to launch a clinical trial using its innovative single-channel ECG mental health screening algorithm, as announced on 7 November 2024. In collaboration with the Greater Los Angeles Veterans Research and Education Foundation and the US Department of Veterans Affairs, the trial protocol has been submitted to the VA’s Institutional Review Board for approval. A Cooperative Research and Development Agreement is also in progress. This AI-driven algorithm, an extension of TrivarX’s lead asset MEB-001, accurately screens for cMDE using heart rate and heart rate variability metrics. Phase 2 trial results on 195 patients showed 87% sensitivity and 67% specificity. Read more: https://lnkd.in/gEJY3Aep #TRI #ASX #ASXnews #mentalhealth #health

TrivarX (ASX:TRI) is pleased to provide the Company's Half Year Report ended 31 December 2024: https://lnkd.in/dgMFKsin #TRI #AI #tech #health #ASX #ASXnews

TrivarX (ASX:TRI) Quarterly Activities Report: MEB-001 regulatory pathway advanced alongside ongoing algorithm development to expand total addressable market. Read more: https://lnkd.in/gxJ8_jui #TRI #AI #tech #health #ASX #ASXnews

??Non-Executive Chairman David Trimboli: “Recent positive engagement with the FDA has given the Company considerable confidence in its clinical development and regulatory pathway for MEB-001.” Read our recent announcement: https://lnkd.in/g6KT89pg #TRI #ASX #AI #health

?? Positive engagement with FDA following pre-submission meeting for MEB-001 - Meeting provided TRI with confidence on clinical trial design for planned pivotal trial of MEB-001 prior to formal regulatory submission More: https://lnkd.in/g6KT89pg $#TRI #ASX #AI #health

??Non-Executive Chairman David Trimboli: “The Australian government’s R&D program greatly assists companies like TrivarX to advance innovative solutions.” Read our recent announcement: https://lnkd.in/gHBM8gNA #TRI #ASX #AI #health

$1.03m R&D Tax Incentive received -Incentive supports Phase 2 SAMDE study, pivotal study prep, & sleep software development. -Program offers 43.5% tax offset for eligible R&D, boosting innovation in Australia. Read more: https://lnkd.in/gHBM8gNA #AI #mentalhealth #TRI #ASX #ASXtech #ASXnews

Chairman's update at the TrivarX Annual General Meeting held today: https://lnkd.in/gJg-KgRc #TRI #ASX #AGM